Structure Therapeutics Aktie News

Investors are well aware of the explosive growth potential in weight loss drug stocks. That growth began last year with Eli Lilly (NYSE: LLY ) and Novo Nordisk (NYSE: NVO ).

Amgen, Viking Therapeutics, Altimmune, AstraZeneca, Boehringer Ingelheim and Zealand Pharma are making encouraging progress on their own treatments.

Investors continue to search for the next big weight loss drug stocks following the success of Eli Lilly (NYSE: LLY ) and Novo Nordisk (NYSE: NVO ). So-called GLP-1 receptor agonists represent a fundamental change in weight loss treatment.

A couple of big-picture trends in biotech could add up to a nice investment opportunity. First, corporate buyouts are back in style.

With the major indexes at or near record highs, it's been easy to overlook the performance of the small-cap Russell-2000 Index. While the index is “only” up about 5% in 2024, it's up 21% in the past 12 months, and is slowly starting to catch up to the market rally.

Contenders are beginning to emerge from the lab, some with the potential to unseat Lilly's Zepbound and Novo's Wegovy.

SAN FRANCISCO, March 08, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today announced that Raymond Stevens, Ph.D., the Company's Founder and Chief Executive Officer, will participate in a fireside chat at the Leerink Partners Glo...

Topline GSBR-1290 Phase 2a 12-week obesity data, as well as data from formulation bridging and titration optimization study, on track for latter half of the second quarter 2024